Conference Day Two
October 1, 2025
8:00 am One-on-One PartneringTM Meeting Schedule Starts
8:30 am Chair’s Opening Remarks
Viewing Engagers Against Competing Drug Modalities & as Complementary Approaches
8:40 am Company Presentations
Synopsis
Are you positioning your engagers strategically against other drug modalities or as complementary approaches?
- The liquid tumor space is crowded but still presents a best-in-class opportunity for engagers. Meanwhile first-in-class status is still on the cards for the solid tumor space and across autoimmune and immunology applications. Demonstrate the economics of pursuing de-risked v novel targets across different cancers here
- Showcase your innovative engager approach in one of our limited, standalone presentation slots. You’ll have the full stage to capture the attention of pharma and investor decision-makers to drive partnership opportunities
- Ensure maximum visibility and engagement with the most relevant decision-makers shaping the future of immune cell engager deal-making across both oncology and immunology
9:20 am Panel Discussion: Maximizing the Market Opportunity of Multispecific Engagers or Combinatorial Treatment Strategies Involving Engagers to Cement the Role of Engagers in the Global Therapeutic Arsenal
Synopsis
- How are engagers bringing something different compared to existing modalities in terms of good efficacy, durability of response, and better safety profiles by creating memory T cells and immune surveillance, as opposed to just huge but short-lived efficacy outcomes?
- How can engagers be complementary to other drug modalities, such as ADCs, to achieve improved patient outcomes?
- Comparing the growth trajectory of engagers against other drug modalities – how do engagers compare and what is the growth runway for engagers?
9:50 am Morning Break & Networking
10:00 am One-on-One PartneringTM Portal Meeting Schedule Available during Extended Break
Synopsis
With Day One being an opportunity to establish connections and break the ice, leverage extended breaks on
Day Two’s schedule to sit down with slide decks and make a lasting impression
Enabling Engager Asset Differentiation to Optimize Engager Safety
11:30 am Company Presentations
Synopsis
Differentiating your engager through selectivity strategies to optimize safety?
- Clinical management of cytokine release syndrome and off-target toxicity has progressed significantly, but engager drug design is still being refined to differentiate assets
- Showcase your innovative engager approach in one of our limited, standalone presentation slots. You’ll have the full stage to capture the attention of pharma and investor decision-makers to drive partnership opportunities
- Ensure maximum visibility and engagement with the most relevant decision-makers shaping the future of immune cell engager deal-making across both oncology and immunology
12:10 pm Panel Discussion: Improving Engager Safety Through Tunable Selectivity Strategies Such as Avidity, Masking &/or Design Approaches to Enable Asset Differentiation
Synopsis
- How are we differentiating engagers through masking technologies for conditional activation or leveraging peptide MHC restriction?
- How are biotech demonstrating the agility of engagers with tunable avidity through multiple binding sites and target selectivity that regulates T-cell activity, increases potency, and prolongs duration of response?
- What are the evolving safety profiles of engagers being achieved through better clinical management of cytokine release syndrome (CRS) and off-target toxicities?
- How else are biotech optimizing engager safety through engager design approaches?
- What are the data needs for manufacturing due diligence for engagers with complex designs?
- How do engagers compare to other drug modalities in terms of safety, efficacy, scientific complexity and costeffectiveness to manufacture, taking into account market size considerations for different disease applications?
12:40 pm Lunch Break & Networking
Synopsis
Continue to use meeting spaces in the room adjacent to the talks as a last opportunity to
sit down with important contacts
1:00 pm One-on-One PartneringTM Portal Meeting Schedule Available Across Lunch
Enabling Engager Asset Differentiation Through Novel Targets & Mechanisms of Action
2:00 pm Company Presentations
Synopsis
Want to highlight novel targets beyond CD20 & CD3 or elevate innovative mechanisms of action?
- Novel targets, mechanisms, or combinations of targets provide the opportunity to increase patient and market size opportunities for engagers
- Showcase your innovative engager approach in one of our limited, standalone presentation slots. You’ll have the full stage to capture the attention of pharma and investor decision-makers to drive partnership opportunities
- Ensure maximum visibility and engagement with the most relevant decision-makers shaping the future of immune cell engager deal-making across both oncology and immunology
2:40 pm Panel Discussion: Improving Engager Efficacy by Targeting Different Cell Lineages, Harnessing Novel Target Combinations & Novel Ways to Combine Targets to Enable Asset Differentiation
Synopsis
- Discussing what even makes a “good” immune cell engager target – do targets need to be exquisitely specific or are there any targets that are sufficiently broad?
- What co-stimulatory molecules are being combined with CD3 to improve efficacy and achieve a sustained response? How are co-stimulatory targets being prioritized against other targets?
- Exploring the evolution of engagers from cell therapy and T-cell targeting to innovation trends in terms of targeting different immune cells or immune cell subtypes – What is the emerging landscape of NK cell, myeloid cell, gamma delta T cell engagers? What are their benefits, applications, and deals to support their success in immunology?
2:40 pm Panel Discussion: Improving Engager Efficacy by Targeting Different Cell Lineages, Harnessing Novel Target Combinations & Novel Ways to Combine Targets to Enable Asset Differentiation
Synopsis
- Discussing what even makes a “good” immune cell engager target – do targets need to be exquisitely specific or are there any targets that are sufficiently broad?
- What co-stimulatory molecules are being combined with CD3 to improve efficacy and achieve a sustained response? How are co-stimulatory targets being prioritized against other targets?
- Exploring the evolution of engagers from cell therapy and T-cell targeting to innovation trends in terms of targeting different immune cells or immune cell subtypes – What is the emerging landscape of NK cell, myeloid cell, gamma delta T cell engagers? What are their benefits, applications, and deals to support their success in immunology?
Understanding Strategic Priorities & Dealmaking Trends for Engagers Internationally to Plot the Next Transformative Immune Cell Engager Deal
3:10 pm Panel Discussion: Assessing the Robust Deal Activity of Engagers Internationally & Discussing Creative Deal Structures
Synopsis
- Leveraging key lessons learned from deal structures and due diligence on engagers – how have recent deals been structured? What data was necessary for those deals?
- What are the robust preclinical data packages that have enabled pre-IND deal-making to take place and how do data packages differ for clinical stage engagers?
- Getting advice on how to structure an early-stage agreement
- Building awareness of competitive engager assets and platform technologies by reviewing patent literature across all geographies
- What economics have driven recent engager deal structures globally, and how do we anticipate this might change in an evolving geopolitical landscape?